tidytlg
A tables-listings-graphs package that reached CRAN and then went quiet.
Comparison · Analytics
DoseFinding vs ggsurvfit
A side-by-side editorial comparison of DoseFinding and ggsurvfit — release velocity, themes, recent moves, and the top alternatives to consider.
DoseFinding vs ggsurvfit: at a glance
What is DoseFinding?
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
What is ggsurvfit?
ggsurvfit is in correctness-and-compatibility mode, not feature mode.
The package draws survival and cumulative-incidence curves on a ggplot2 grammar, with risk tables, p-values and quantile annotations. Recent releases are entirely fixes and upstream tracking: ggplot2 v4.0.0 compatibility in 2025, and a 2026 patch correcting a Gray-test p-value that could be reported for the wrong competing event.
DoseFinding vs ggsurvfit: editorial side-by-side
DoseFinding
0.0ANALYTICS
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
◆ Current state
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
◆ Where it's heading
The pattern before the handover was maintenance — R-devel compliance, a bug fix, a link. After it, each release carries a named methodological addition with an acknowledged contributor, plus documentation to match: a longitudinal analysis vignette shipped alongside the interim power work. Housekeeping continues underneath, mostly clearing deprecated ggplot2 interfaces, aes_string in one release and qplot in the next.
◆ Prediction
Given the last two releases each added one method with a supporting vignette, expect the next to follow the same shape. Both additions so far extend the package beyond fixed dose-response fitting, so adaptive and interim methodology is the more likely direction.
ggsurvfit
2.5ANALYTICS
ggsurvfit is in correctness-and-compatibility mode, not feature mode.
◆ Current state
The package draws survival and cumulative-incidence curves on a ggplot2 grammar, with risk tables, p-values and quantile annotations. Recent releases are entirely fixes and upstream tracking: ggplot2 v4.0.0 compatibility in 2025, and a 2026 patch correcting a Gray-test p-value that could be reported for the wrong competing event.
◆ Where it's heading
The feature surface settled around 1.0.0, when risk-table alignment was exported and colour and linetype defaults became configurable. Since then the work is keeping pace with survival, ggplot2 and tidycmprsk changes, and closing cases where the plotted curve and the annotation disagreed — the p-value matched by position rather than name, confidence limits swapped for multi-state models, quantiles read off a plateau.
◆ Prediction
Expect the next release to track upstream survival or ggplot2 changes rather than add plotting features; the CDISC censoring convention adopted in Surv_CNSR() suggests further alignment with clinical data standards is the likelier direction.
Alternatives to DoseFinding and ggsurvfit
Other Analytics products tracked by Sparkpulse, ranked by recent ship velocity. Each card links to a full editorial trajectory and lets you pivot into a head-to-head comparison with either DoseFinding or ggsurvfit.
Tplyr
Tplyr made clinical summary tables explain where every number came from.
rlistings
Clinical listings that keep inheriting their hardest problem — pagination — from the layer below.
hoardr
A cache-directory helper that has shipped nothing but CRAN-triggered patches for seven years.
gigs
gigs redesigned its whole conversion API for rOpenSci, then spent three releases getting the docs to build.
riem
A weather-data client that keeps rewriting its HTTP layer while slowly tightening its API.
See all DoseFinding alternatives → · See all ggsurvfit alternatives →
Recent activity from DoseFinding and ggsurvfit
Latest ship moves from both products, interleaved chronologically. ⚡ = editorial spark.
- 21d agoggsurvfitGray-test p-values matched to the plotted outcome by name
- 10mo agoggsurvfitggplot2 v4.0.0 compatibility and multi-state CI label fix
- 1y agoDoseFindingConditional and predictive power for interim analyses
- 1y agoDoseFindingModel averaging arrives for dose-response fitting ⚡
- 1y agoDoseFindingPackage moves to openpharma under new maintainership
- 2y agoggsurvfitNegative follow-up times and a cloglog transformation
- 2y agoDoseFindingCompliance update for R-devel
- 2y agoggsurvfitAesthetic defaults become switchable and alignment is exported
- 2y agoggsurvfitConfidence limits corrected for monotonicity-reversing transforms
- 3y agoDoseFindingpowMCTBinCount bug fix
- 3y agoggsurvfitGlue syntax in risk tables and coxph model support
Frequently asked questions
What is the difference between DoseFinding and ggsurvfit?
They serve adjacent needs but don't currently overlap on shipped themes. ggsurvfit is currently shipping more aggressively (velocity 2.5 vs 0.0), with 0 editorial sparks in the last 30 days against 0. See the at-a-glance table above for a side-by-side breakdown of velocity, recent sparks, and editorial themes.
Is DoseFinding better than ggsurvfit?
Sparkpulse doesn't pick a winner — we score release velocity, not feature parity. ggsurvfit is currently shipping more aggressively (velocity 2.5 vs 0.0), with 0 editorial sparks in the last 30 days against 0. For your specific use case, the alternatives sections above list other Analytics products to evaluate alongside.
What are the best alternatives to DoseFinding?
Top DoseFinding alternatives in Analytics are ranked by recent ship velocity. Browse the "DoseFinding alternatives" section above for the current picks, or visit /alternatives/dosefinding for the full list with editorial commentary on each.
What are the best alternatives to ggsurvfit?
Top ggsurvfit alternatives in Analytics are ranked by recent ship velocity. Browse the "ggsurvfit alternatives" section above for the current picks, or visit /alternatives/ggsurvfit for the full list with editorial commentary on each.